Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
GlobeNewswire
*CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- *Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq:..